High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: An observational sutdy

Nephrology Dialysis Transplantation

Volumn 18, Issue 6, 2003, Pages 1135-1141

  Helldén, Anders ^a   Odar Cederlöf, Ingegerd ^a   Diener, Per ^a   Barkholt, Lisbeth ^a   Medin, Charlotte ^a   Svensson, Jan Olof ^a   Säwe, Juliette ^a   Ståhle, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

9 carboxymethoxymethylguanine; Acyclovir; Adverse effects; Neuropsychiatric; Renal failure

Indexed keywords

9 CARBOXYMETHOXYMETHYLGUANINE; ACICLOVIR; CREATININE; DRUG METABOLITE; GUANINE DERIVATIVE; UNCLASSIFIED DRUG; VALACICLOVIR;

ABDUCENS NERVE DISEASE; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ATAXIA; AUDITORY HALLUCINATION; COMA; CONFIDENCE INTERVAL; CONFUSION; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CREATININE CLEARANCE; DISORIENTATION; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DYSARTHRIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERREFLEXIA; INVOLUNTARY MOVEMENT; LETHARGY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MYOCLONUS; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RESTLESSNESS; SENSITIVITY AND SPECIFICITY; SLURRED SPEECH; SOMNOLENCE; TREMOR; VERTIGO; VISUAL HALLUCINATION;

EID: 0038346056     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg119     Document Type: Article

References (20)

1. Cohen SM, Minkove JA, Zebley JW 3rd, Mulholland JH. Severe but reversible neurotoxicity from acyclovir. Ann Intern Med 1984; 100: 920.
2. Bataille P, Devos P, Noel JL, Dautrevaux C, Lokiec F. Psychiatric side-effects with acyclovir. Lancet 1985; II: 724.
3. Saral R, Burns W, Laskin O, Santos G, Lietman P. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized double-blind controlled trial in bone-marrow transplant recipients. N Engl J Med 1981; 305: 63-67
4. Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921-925
5. Krigel R. Reversible neurotoxicity due to oral acyclovir in a patient with chronic lymphocytic leukemia. J Infect Dis 1986; 154: 189.
6. Linssen-Schuurmans C, van Kan E, Feith G, Uges D. Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit 1998; 20: 385-386
7. Mataix AL, Duarte J, Revuelta K et al. Oral acyclovir and neurologic adverse effects in endstage renal disease. Ann Pharmacother 1994; 28: 961-962
8. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157: 385-388
9. de Knegt RJ, van der Pijl H, van Es LA. Acyclovir-associated encephalopathy, lack of relationship between acyclovir levels and symptoms. Nephrol Dial Transplant 1995; 10: 1775-1777
10. Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20: 647-649
11. de Miranda P, Burnette TC. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab Dispos 1994; 22: 55-59
12. Blum RM, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982; 73: 186-192
13. de Miranda P, Whitley RJ, Blum MR et al. Ayclovir kinetics after intravenous infusion. Clin Pharmacol Ther 1979; 26: 718-728
14. Svensson JO, Barkholt L, Säwe J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 1996; 690: 363-366
15. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12 [Suppl B]: 29-37
16. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administrations to humans. Antimicrob Agents Chemother 1995; 39: 2759-2764
17. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470
18. Schwartz G, Brion L, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987; 34: 571-590
19. Guilhem I, Charasse C, Gary J et al. Neurotoxicité de l'aciclovir chez le dialys péritonéal à propos d'un cas. Nephrologie 1991; 12: 241-243
20. Krieble B, Rudy D, Glick M, Clayman M. Case report: acyclovir neurotoxicity and nephrotoxicity - the role for hemodialysis. Am J Med Sci 1993; 305: 36-39